NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
Market Cap & Net Worth: NEWRON PHARMACEUT. EO-20 (NP5)
NEWRON PHARMACEUT. EO-20 (XETRA:NP5) has a market capitalization of $352.01 Million (€342.93 Million) as of March 19, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #12614 globally and #1342 in its home market, demonstrating a -11.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NEWRON PHARMACEUT. EO-20's stock price €17.18 by its total outstanding shares 19960994 (19.96 Million).
NEWRON PHARMACEUT. EO-20 Market Cap History: 2022 to 2026
NEWRON PHARMACEUT. EO-20's market capitalization history from 2022 to 2026. Data shows growth from $30.94 Million to $352.01 Million (95.64% CAGR).
NEWRON PHARMACEUT. EO-20 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NEWRON PHARMACEUT. EO-20's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.75x
NEWRON PHARMACEUT. EO-20's market cap is 3.75 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
12.17x
NEWRON PHARMACEUT. EO-20's market cap is 12.17 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $30.94 Million | $6.09 Million | -$17.49 Million | 5.08x | N/A |
| 2023 | $108.59 Million | $9.06 Million | -$16.22 Million | 11.99x | N/A |
| 2024 | $192.81 Million | $51.39 Million | $15.84 Million | 3.75x | 12.17x |
Competitor Companies of NP5 by Market Capitalization
Companies near NEWRON PHARMACEUT. EO-20 in the global market cap rankings as of March 19, 2026.
Key companies related to NEWRON PHARMACEUT. EO-20 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NEWRON PHARMACEUT. EO-20 Historical Marketcap From 2022 to 2026
Between 2022 and today, NEWRON PHARMACEUT. EO-20's market cap moved from $30.94 Million to $ 352.01 Million, with a yearly change of 95.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €352.01 Million | -34.80% |
| 2025 | €539.90 Million | +180.02% |
| 2024 | €192.81 Million | +77.55% |
| 2023 | €108.59 Million | +250.99% |
| 2022 | €30.94 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of NEWRON PHARMACEUT. EO-20 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $352.01 Million USD |
| MoneyControl | $352.01 Million USD |
| MarketWatch | $352.01 Million USD |
| marketcap.company | $352.01 Million USD |
| Reuters | $352.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.